# The Psychological Impact of COVID-19 Pandemic on People With Multiple Sclerosis

**Authors:** Francesco Motolese, Mariagrazia Rossi, Giuliano Albergo, Domenica Stelitano, Marialucia Villanova, Vincenzo Di Lazzaro, Fioravante Capone

PMC · DOI: 10.3389/fneur.2020.580507 · Frontiers in Neurology · 2020-10-30

## TL;DR

The study found that the COVID-19 lockdown had a greater negative impact on the mental health of people with multiple sclerosis compared to healthy individuals.

## Contribution

The study specifically examines the psychological effects of the pandemic on people with multiple sclerosis in Italy.

## Key findings

- Patients with MS had higher depression, fatigue, and sleep disturbance scores than healthy controls.
- Unemployment was linked to worse mental health outcomes in the MS group.
- One in five MS patients reported new or worsened symptoms during the pandemic.

## Abstract

Objective: The coronavirus disease 2019 (COVID-19) has radically changed the world in a few weeks. Italy has been one of the first and most affected countries with more than 30,000 deaths up to now. Public health measures as quarantine or national lockdown are necessary to limit the spread of infectious diseases, but it is unsurprising that depriving people of their liberty has negative psychological effects. This is especially the case for people with chronic diseases, including neurological conditions like multiple sclerosis (MS). People with MS (PwMS) have a higher burden of neuropsychiatric comorbidities and are known to undertake maladaptive coping strategies in stress conditions. The aim of the present study is to investigate the impact of COVID-19 pandemic lockdown on mental health of an Italian cohort of PwMS in comparison with healthy controls (HCs).

Methods: A total of 60 PwMS and 50 HCs (chosen among patients' cohabitants) were asked to answer a Web-based survey. This survey inquired about the impact of COVID-19 on patient's quality of life, job, and daily routine. Mood, fatigue, and sleep quality were evaluated using the Beck Depression Inventory II (BDI-II), the Generalized Anxiety Disease 7 (GAD-7), the Fatigue Severity Scale (FSS), and the Pittsburgh Sleep Quality Index (PSQI).

Results: Overall, patients had higher scores of BDI, FSS, and PSQI, and these differences were statistically significant (p < 0.05). When we looked at the subscores of the BDI, we detected a statistically significant difference for the neurovegetative part—that concerns with sleep, appetite, sex, and quality of sleep (p < 0.05). One out of five patients reported new symptoms or worsening of known symptom, in particular, sensory disturbances, and fatigue. However, no symptoms were severe enough to require hospitalization. When we looked for correlations among variables, we found that there was a significant relationship between unemployment and BDI total score, GAD-7, and PSQI in MS group. The presence of new symptoms or the worsening of symptoms positively related to FSS and to PSQI.

Discussion: We identified that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic had a significant impact on the psychological status of patients with MS. Compared with the general population, PwMS presented a higher burden of depressive symptoms, a worse sleep quality and perceived an increase in fatigue level, one of the most disabling symptoms of MS. The COVID-19 epidemic poses a challenge to psychological resilience. More studies are warranted to better understand the long-term consequences of the pandemic on mental health of vulnerable people during the disease outbreaks.

## Linked entities

- **Diseases:** multiple sclerosis (MONDO:0005301), coronavirus disease 2019 (MONDO:0100096)

## Full-text entities

- **Diseases:** Psychiatric symptoms (MESH:D001523), confusion (MESH:D003221), sensory disturbances (MESH:D012678), deaths (MESH:D003643), MS (MESH:D009103), emotional distress (MESH:D012128), cognitive (MESH:D003072), GAD-7 (MESH:C000726808), limb weakness (MESH:D018908), post-traumatic stress symptoms (MESH:D013313), anxiety (MESH:D001007), COVID-19 (MESH:D000086382), sleep disturbances (MESH:D012893), autonomic nervous system hyperactivity (MESH:D001342), coronavirus (MESH:D018352), Depression (MESH:D003866), PwMS (MESH:C000719191), inflammatory disease of the central nervous system (MESH:D002493), neurodegeneration (MESH:D019636), mental fatigue (MESH:D005222), diseases (MESH:D004194), optic neuritis (MESH:D009902), infected (MESH:D007239), Fatigue (MESH:D005221), diplopia (MESH:D004172), anxiety disorder (MESH:D001008), disability (MESH:D009069), sensory loss (MESH:C580162), somatic symptoms (MESH:D000071896), infectious diseases (MESH:D003141), neuropsychiatric (MESH:C000631768), inflammatory (MESH:D007249), neuroprogressive disorders (MESH:D009358), neurovegetative disturbances (MESH:D014832), mood disorder (MESH:D019964), chronic diseases (MESH:D002908), HPA axis (MESH:D007029), motor or cognitive failures (MESH:D051437), sleep disruption (MESH:D019958)
- **Chemicals:** Dimethyl fumarate (MESH:D000069462), Glatiramer acetate (MESH:D000068717), dopamine (MESH:D004298), Teriflunomide (MESH:C527525), antidepressive drugs (-), cortisol (MESH:D006854), Natalizumab (MESH:D000069442)
- **Species:** Homo sapiens (human, species) [taxon 9606], Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC7662111/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC7662111/full.md

## References

56 references — full list in the complete paper: https://tomesphere.com/paper/PMC7662111/full.md

---
Source: https://tomesphere.com/paper/PMC7662111